AQST
Price
$3.77
Change
-$0.06 (-1.57%)
Updated
Aug 29 closing price
Capitalization
456.07M
71 days until earnings call
TLRY
Price
$1.38
Change
-$0.09 (-6.12%)
Updated
Aug 29 closing price
Capitalization
1.52B
31 days until earnings call
Interact to see
Advertisement

AQST vs TLRY

Header iconAQST vs TLRY Comparison
Open Charts AQST vs TLRYBanner chart's image
Aquestive Therapeutics
Price$3.77
Change-$0.06 (-1.57%)
Volume$1.04M
Capitalization456.07M
Tilray Brands
Price$1.38
Change-$0.09 (-6.12%)
Volume$51.26M
Capitalization1.52B
AQST vs TLRY Comparison Chart in %
Loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AQST vs. TLRY commentary
Sep 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a Buy and TLRY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 01, 2025
Stock price -- (AQST: $3.77 vs. TLRY: $1.38)
Brand notoriety: AQST: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AQST: 80% vs. TLRY: 83%
Market capitalization -- AQST: $456.07M vs. TLRY: $1.52B
AQST [@Pharmaceuticals: Generic] is valued at $456.07M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $1.52B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $69.31B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, AQST is a better buy in the long-term than TLRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 3 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • AQST’s TA Score: 3 bullish, 6 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TLRY is a better buy in the short-term than AQST.

Price Growth

AQST (@Pharmaceuticals: Generic) experienced а -5.28% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was +20.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.55%. For the same industry, the average monthly price growth was +67.47%, and the average quarterly price growth was +80.21%.

Reported Earning Dates

AQST is expected to report earnings on Nov 10, 2025.

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.55% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.52B) has a higher market cap than AQST($456M). AQST YTD gains are higher at: 5.899 vs. TLRY (3.759). AQST has higher annual earnings (EBITDA): -47.5M vs. TLRY (-2.13B). TLRY has more cash in the bank: 256M vs. AQST (60.5M). AQST has less debt than TLRY: AQST (40.3M) vs TLRY (329M). TLRY has higher revenues than AQST: TLRY (821M) vs AQST (44.1M).
AQSTTLRYAQST / TLRY
Capitalization456M1.52B30%
EBITDA-47.5M-2.13B2%
Gain YTD5.8993.759157%
P/E RatioN/AN/A-
Revenue44.1M821M5%
Total Cash60.5M256M24%
Total Debt40.3M329M12%
FUNDAMENTALS RATINGS
AQST vs TLRY: Fundamental Ratings
AQST
TLRY
OUTLOOK RATING
1..100
2941
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
4634
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AQST's Valuation (37) in the Pharmaceuticals Major industry is in the same range as TLRY (53) in the Biotechnology industry. This means that AQST’s stock grew similarly to TLRY’s over the last 12 months.

AQST's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as TLRY (100) in the Biotechnology industry. This means that AQST’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's SMR Rating (99) in the Biotechnology industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that TLRY’s stock grew similarly to AQST’s over the last 12 months.

TLRY's Price Growth Rating (34) in the Biotechnology industry is in the same range as AQST (46) in the Pharmaceuticals Major industry. This means that TLRY’s stock grew similarly to AQST’s over the last 12 months.

TLRY's P/E Growth Rating (94) in the Biotechnology industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that TLRY’s stock grew similarly to AQST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTTLRY
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bearish Trend 6 days ago
78%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 6 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EIVFX14.600.01
+0.07%
Allspring Special Large Cap Value R6
DFDPX40.22-0.14
-0.35%
DF Dent Premier Growth Investor
QICNX16.88-0.10
-0.59%
AQR International Multi-Style N
PIORX44.96-0.43
-0.95%
Victory Pioneer R
LEVOX12.04-0.33
-2.67%
Lazard US Equity Concentrated Open

AQST and

Correlation & Price change

A.I.dvisor indicates that over the last year, AQST has been loosely correlated with HROW. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if AQST jumps, then HROW could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
-1.57%
HROW - AQST
34%
Loosely correlated
+0.03%
ESPR - AQST
32%
Poorly correlated
+0.45%
BCRX - AQST
30%
Poorly correlated
-1.89%
SCYX - AQST
29%
Poorly correlated
-2.17%
TLRY - AQST
28%
Poorly correlated
-6.12%
More